Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Colorado › Grand Junction
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Grand Junction, CO keessatti
Qorannoo 8 Kansara Qara'a Non-Small Cell f Grand Junction fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Namoota walitti qabaa jiraSadarkaa 3
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Namoota walitti qabaa jiraSadarkaa 3
- Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132), Grand Junction
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Namoota walitti qabaa jiraSadarkaa 3
- Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
- Intermountain Health St. Mary's Regional Hospital, Grand Junction
- Intermountain Health, Grand Junction
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Namoota walitti qabaa jiraSadarkaa 3
- Local Institution - 0500, Grand Junction
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Study Site, Grand Junction
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Grand Junction
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Namoota walitti qabaa jiraSadarkaa 3
- Intermountain Health St. Mary's Regional Hospital ( Site 0116), Grand Junction
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Grand Junction keessatti
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.